Skip to main navigation Recent News Investors Contact Us Home Our Focus Culture & Careers Home > Investors > Investor Home Investor Home Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. For more information, please visit www.avadel.com. Stock Information : (Common Stock) Data as of Recent News 11/22/21 Avadel Pharmaceuticals to Present at Upcoming Investor Conferences 11/09/21 Avadel Pharmaceuticals to Present at Upcoming Investor Conferences in November more » Upcoming Events 12/01/21 2:00 PM EST Evercore ISI 4th Annual HealthCONx Conference Listen to webcast Add to Outlook Add to Google Calendar more » Data Provided by Refinitiv. Minimum 15 minutes delayed. Tools Print Page RSS E-mail Alerts Investors News & Events Stock Information Financial Information Corporate Governance Shareholder Services Investor Relations Our Focus Culture & Careers Investors Recent News Contact Us Privacy Policy Corporate Compliance Terms and Conditions The Avadel logo, the droplet brand mark, and other brands are trademarks of an Avadel company. © 2021 Avadel. All rights reserved. PM-US-AVGEN-0071